Ai primi test porta sviluppo di cellule immunitarie anti-tumore
Risultati per: Scoperto nuovo biomarker per il cancro al colon-retto
Questo è quello che abbiamo trovato per te
Biomarker-Guided Antibiotic Duration for Patients With Suspected Sepsis
This clinical trial assessed whether treatment protocols for monitoring C-reactive protein or procalcitonin safely reduced the amount of time critically ill adults with suspected sepsis received antibiotics while maintaining treatment safety measured by 28-day all-cause mortality.
Nuova speranza per il trattamento del cancro colorettale
Accordo tra Aiom e Fondazione Airc per la prevenzione del cancro
Si rafforza collaborazione tra Istituti, verso progetti comuni
Un esame del sangue identifica il cancro al pancreas
Mangiare yogurt può ridurre il rischio di specifici tumori del colon-retto
Low & Anaplastic Grade Glioma Umbrella Study of MOlecular Guided TherapieS (LUMOS-2): study protocol for a phase 2, prospective, multicentre, open-label, multiarm, biomarker-directed, signal-seeking, umbrella, clinical trial for recurrent IDH mutant, grade 2/3 glioma
Introduction
All grade 2/3 gliomas are incurable and at the time of inevitable relapse, patients have significant unmet needs with few effective treatments. This study aims to improve outcomes by molecular profiling of patients at relapse, then matching them with the best available drug based on their molecular profile, maximising the chances of patient benefit while simultaneously testing multiple novel drugs.
Methods and analysis
Low & Anaplastic Grade Glioma Umbrella Study of MOlecular Guided TherapieS (LUMOS-2) will be an international, phase 2, multicentre, open-label, biomarker-directed, umbrella clinical trial for recurrent isocitrate dehydrogenase mutant, histologically grade 2/3 gliomas. Investigational treatment will be assigned based on molecular profiling of contemporaneous tissue obtained at disease relapse using next-generation sequencing. LUMOS-2 will begin with three therapeutic treatment arms: paxalisib, cadonilimab and selinexor. Patient molecular profiles will be assessed by an expert, multidisciplinary Molecular Tumour Advisory Panel. Patients whose molecular profile is considered suitable for a targeted agent like paxalisib will be allocated to that arm, others will be randomised to the available arms of the trial. The primary endpoint is progression-free survival at 6 months. Secondary objectives include assessment of overall survival, response rate, safety and quality of life measures. Two additional therapeutic arms are currently in development.
Ethics and dissemination
Central ethics approval was obtained from the Sydney Local Health District Ethics Review Committee, Royal Prince Alfred Hospital Zone, Sydney, Australia (Approval: 2022/ETH02230). Other clinical sites will provide oversight through local governance processes, including obtaining informed consent from suitable participants. A report describing the results of the study will be submitted to international meetings and peer-reviewed journals.
Trial registration number
ACTRN12623000096651.
Arte-terapia per i bimbi con cancro all'associazione Peter Pan
L’organizzazione accoglie a Roma chi viene da fuori per le cure
Cancro ovarico: Standard di qualità
UniBa studia intelligenza artificiale applicata a ricerca cancro
E’ partner del progetto ‘European cancer imaging – Eucaim’
Giornata contro il cancro: 1.500 nuovi pazienti nel 2024
Ast Pesaro-Urbino presenta i numeri del territorio
Campitiello (Ministero Salute), 'accesso più equo alle terapie anti cancro'
‘Gli strumenti ci sono ma bisogna applicarli’
Bianca Balti, 'il cancro mi ha fatto amare molto di più la vita'
Lungo post della modella che sarà sul palco di Sanremo
Un test delle urine per il cancro alla prostata potrebbe essere utilizzato a casa
Giornata mondiale contro il cancro, 12 tipi legati all'obesità
Oncologi,ma meno del 50% cittadini riceve consigli su stili vita
Ast Ancona estende screenin colon retto a donne e uomini
Per diagnosi precoce del tumore tra i 70 e 74 anni